After the first part of this year’s Generics Bulletin Top 50 showed two new players entering the top 10 and the second looked at how firms in the middle of our ranking were faring (see sidebar), this third section of our annual feature reflects positive and negative changes among lower-placed firms that have led to some meaningful movements at the bottom of the table in 2023.
Leading off our third table is Endo, which jumps up from position 34 last year to 31st place this year, amid growth for the company in our lead category of Generics/Biosimilars/APIs/OTC sales and as a few firms in
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?